Puma to develop Pfizer investigational cancer drug
Neratinib is a multi-targeted, irreversible tyrosine kinase inhibitor (TKI) oral drug which targets the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases. Neratinib is being studied in the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.